LogicFlo AI, a Boston-based AI platform, has raised $2.7 million in a seed funding round led by Lightspeed, with participation from leading healthcare and enterprise AI investors.
The funds raised will be used for global expansion across pharmaceutical, biotech, and medtech organizations, and enable deeper deployment with global clients. LogicFlo AI will also accelerate product development, expand integrations with life sciences systems like Veeva and IQVIA, and grow its go-to-market and technical teams to meet rising industry demand.
Founded in 2024 by Udith Vaidyanathan and Arun Ramakrishnan, LogicFlo AI is an AI agent platform purpose-built for life sciences organizations — designed to help expert teams in medical, regulatory, quality, and commercial functions execute high-stakes work faster, more accurately, and in full compliance.
LogicFlo AI enables experts to complete high-compliance workflows in a fraction of the time, without sacrificing accuracy or oversight.
LogicFlo AI’s agents support functions across the entire life sciences value chain: medical writing with literature-based content creation and full referencing; Medical communications and information response generation with SR documents, material for ad boards, congresses, journal articles, commercial content creation with compliant promotional materials and MLR workflow management; regulatory authoring for CTAs, INDs, and safety narratives; quality and compliance documentation including SOPs, deviation reports, and CAPAs and so on.
Udith Vaidyanathan, LogicFlo AI’s co-founder and CEO, talking about the platform said, “We are at a once-in-a-generation inflection point. For the first time, AI agents are capable enough to drive meaningful productivity gains in regulated scientific work, not just possible, but inevitable. While the rest of the world is focused on automation, instead of people, we are building automation for people. LogicFlo AI puts experts firmly at the center. The goal is to empower the brightest people in life sciences do what only they can do – drive medical science forward and help elevate the standard of care.”
Arun Ramakrishnan, LogicFlo AI’s co-founder and CTO, said, “Traditional automation has failed life sciences because it’s too rigid, too brittle, and too out of touch with how people actually work. LogicFlo AI agents are different. They’re intelligent, composable, production-ready, and they understand the nuance of scientific work.”
Rohil Bagga, VP Investments, Lightspeed, said, “We’re thrilled to back LogicFlo AI as they revolutionize how life sciences and biotech organizations operate. Their AI agent platform empowers medical affairs and commercial teams to build agentic workflows across diverse use cases, dramatically boosting productivity. Founders Udith and Arun combine deep domain expertise with exceptional technical acumen—we’re excited to support them as they drive transformation in one of the world’s most critical industries.”
